CEACAM1在代谢功能障碍相关脂肪性肝病中的作用

董凯旋; 陈丹妮; 郑亚; 王玉平; 郭庆红

doi:10.12290/xhyxzz.2024-0035

CEACAM1在代谢功能障碍相关脂肪性肝病中的作用

doi: 10.12290/xhyxzz.2024-0035

董凯旋^1,2,
陈丹妮^1,2,
郑亚^2,3,
王玉平^2,3,
郭庆红^2,3,4, ,

1 兰州大学第一临床医学院, 兰州 730000;
2 兰州大学第一医院消化科, 兰州 730000;
3 兰州大学第一医院甘肃省消化系疾病临床医学研究中心, 兰州 730000;
4 兰州大学第一医院消化内镜中心, 兰州 730000

详细信息

通讯作者:
郭庆红,E-mail:gqh@lzu.edu.cn

中图分类号: G575.5；R589.2
计量
- 文章访问数: 24
- HTML全文浏览量: 3
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-18
- 录用日期: 2024-02-04
- 网络出版日期: 2024-03-09

The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease

DONG Kaixuan^1,2,
CHEN Danni^1,2,
ZHENG Ya^2,3,
WANG Yuping^2,3,
GUO Qinghong^{2,3,4
, ,}

1 The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China;
2 Department of Gastroenterology, the First Hospital of Lanzhou University, Lanzhou 730000, China;
3 Gansu Province Clinical Research Center for Digestive Diseases, the First Hospital of Lanzhou University, Lanzhou 730000, China;
4 Gastrointestinal Endoscopy Center, the First Hospital of Lanzhou University, Lanzhou 730000, China

摘要

摘要: 癌胚抗原相关细胞粘附分子1(carcinoembryonic antigen-relatedcell adhesion molecule 1，CEACAM1)是一种免疫球蛋白超家族的跨膜蛋白，参与介导细胞粘附、组织转移、免疫反应控制以及机体代谢平衡。研究表明,CEACAM1主要通过促进胰岛素清除以防止脂肪沉积,从而对肝脏发挥保护作用。CEACAM1表达水平下调会导致胰岛素抵抗状态的恶性循环并加重代谢紊乱。由于CEACAM1在控制代谢功能障碍相关脂肪性肝病(metabolic dysfunctionassociated steatotic liver disease,MASLD)中的关键地位，刺激其作用途径或调节其表达水平有望成为MASLD的治疗新方法。本文就CEACAM1在MASLD中的有关研究进展作一综述。
- 代谢功能障碍相关脂肪性肝病 /
- 癌胚抗原相关细胞粘附分子1 /
- 胰岛素清除 /
- 脂质代谢
Abstract: Carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1) is a transmembrane protein of the immunoglobulin superfamily,which is involved in mediating cell adhesion,tissue metastasis,control of immune response,and metabolic homeostasis.Studies have shown that CEACAM1 plays a protective role in the liver by promoting insulin clearance and preventing fat deposition.The down-regulation of the CEACAM1 expression level leads to a vicious cycle of insulin resistance and aggravates metabolic disorders.Because CEACAM1 is critical in controlling metabolic dysfunction-associated steatotic liver disease (MASLD),stimulating its pathway or regulating its expression level is expected to be a new therapeutic approach for MASLD.In this paper,we summarize the research progress of CEACAM1 in MASLD.
- metabolic dysfunction-associated steatotic liver disease /
- carcinoembryonic antigen-related cell adhesion molecule 1 /
- insulin clearance /
- lipid metabolism

HTML全文

参考文献(60)

[1]	Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH):a systematic review[J]. Hepatology (Baltimore, Md), 2023, 77(4):1335-47.
[2]	Loomba R, Wong V W. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Alimentary pharmacology & therapeutics, 2024, 59(2):150-6.
[3]	Harrison S A, Dubourg J, Knott M, et al. Hyperinsulinemia, an overlooked clue, and potential way forward in metabolic dysfunction-associated steatotic liver disease[J]. Hepatology (Baltimore, Md), 2023.
[4]	Yanai H, Adachi H, Hakoshima M, et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments[J]. International journal of molecular sciences, 2023, 24(20).
[5]	Kube-Golovin I, Lyndin M, Wiesehöfer M, et al. CEACAM expression in an in-vitro prostatitis model[J]. Frontiers in immunology, 2023, 14:1236343.
[6]	Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer:interactions with pathogens[J]. Genes & cancer, 2023, 14:12-29.
[7]	Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes[J]. Diagnostic pathology, 2011, 6:40.
[8]	Heinrich G, Ghadieh H E, Ghanem S S, et al. Loss of Hepatic CEACAM1:A Unifying Mechanism Linking Insulin Resistance to Obesity and NonAlcoholic Fatty Liver Disease[J]. Frontiers in endocrinology, 2017, 8:8.
[9]	Lee W H, Najjar S M, Kahn C R, et al. Hepatic insulin receptor:new views on the mechanisms of liver disease[J]. Metabolism:clinical and experimental, 2023, 145:155607.
[10]	Russo L, Muturi H T, Ghadieh H E, et al. Liver-specific rescuing of CEACAM1 reverses endothelial and cardiovascular abnormalities in male mice with null deletion of Ceacam1 gene[J]. Molecular metabolism, 2018, 9:98-113.
[11]	Hajihassan Z, Mohammadpour Saray M, Yaseri A. Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor[J]. Iranian biomedical journal, 2023, 27(4):191-8.
[12]	Dery K J, Kojima H, Kageyama S, et al. Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans[J]. Science translational medicine, 2023, 15(707):eadf2059.
[13]	Fan Y, Yan Z, Li T, et al. Primordial Drivers of Diabetes Heart Disease:Comprehensive Insights into Insulin Resistance[J]. Diabetes & metabolism journal, 2024.
[14]	Schwärzler J, Grabherr F, Grander C, et al. The pathophysiology of MASLD:an immunometabolic perspective[J]. Expert review of clinical immunology, 2023:1-12.
[15]	Vesković M, Šutulović N, Hrnčić D, et al. The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease-The Transition from an Adipocentric to Liver-Centric Approach[J]. Current issues in molecular biology, 2023, 45(11):9084-102.
[16]	Margolis R N, Taylor S I, Seminara D, et al. Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain[J]. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85(19):7256-9.
[17]	刘传, 李丽娟, 王嵘, 等. CEACAM5在肺腺癌中的表达及临床意义[J]. 临床肺科杂志, 2022, 27(02):256-61.
[18]	Najjar S M. Regulation of insulin action by CEACAM1[J]. Trends in endocrinology and metabolism:TEM, 2002, 13(6):240-5.
[19]	马凯, 王鸽, 孙建兵, 等. HopQ与人CEACAM1相互作用的研究进展[J]. 医学综述, 2019, 25(17):3433-7.
[20]	Choice C V, Howard M J, Poy M N, et al. Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors[J]. The Journal of biological chemistry, 1998, 273(35):22194-200.
[21]	Bergman R N, Kabir M, Ader M. The Physiology of Insulin Clearance[J]. International journal of molecular sciences, 2022, 23(3).
[22]	Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis[J]. Hepatology (Baltimore, Md), 2014, 59(6):2178-87.
[23]	De Vries M, El-Morabit F, Van Erpecum K J, et al. Non-alcoholic fatty liver disease:identical etiologic factors in patients with type 1 and type 2 diabetes[J]. European journal of internal medicine, 2022, 100:77-82.
[24]	De Vries M, Westerink J, Kaasjager K, et al. Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus:A Systematic Review and Meta-Analysis[J]. The Journal of clinical endocrinology and metabolism, 2020, 105(12):3842-53.
[25]	Poy M N, Ruch R J, Fernstrom M A, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin[J]. The Journal of biological chemistry, 2002, 277(2):1076-84.
[26]	Yousef A A, Behiry E G, Allah W M A, et al. IRS-1 genetic polymorphism (r.2963G>A) in type 2 diabetes mellitus patients associated with insulin resistance[J]. The application of clinical genetics, 2018, 11:99-106.
[27]	Poy M N, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver[J]. Nature genetics, 2002, 30(3):270-6.
[28]	Nagaishi T, Pao L, Lin S H, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms[J]. Immunity, 2006, 25(5):769-81.
[29]	Mahmoud A M, Szczurek M R, Blackburn B K, et al. Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles[J]. Physiological reports, 2016, 4(16).
[30]	Abu Helal R, Muturi H T, Lee A D, et al. Aortic Fibrosis in Insulin-Sensitive Mice with Endothelial Cell-Specific Deletion of Ceacam1 Gene[J]. International journal of molecular sciences, 2022, 23(8).
[31]	Muturi H T, Ghadieh H E, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis[J]. Metabolism:clinical and experimental, 2023, 144:155562.
[32]	Helal R A, Russo L, Ghadieh H E, et al. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1[J]. Metabolism:clinical and experimental, 2021, 121:154801.
[33]	Yan M, Li H, Xu S, et al. Targeting Endothelial Necroptosis Disrupts Profibrotic Endothelial-Hepatic Stellate Cells Crosstalk to Alleviate Liver Fibrosis in Nonalcoholic Steatohepatitis[J]. International journal of molecular sciences, 2023, 24(14).
[34]	Laurenti M C, Dalla Man C, Varghese R T, et al. Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans[J]. The Journal of clinical endocrinology and metabolism, 2021, 106(6):1702-9.
[35]	Debose-Boyd R A, Ye J. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond[J]. Trends in biochemical sciences, 2018, 43(5):358-68.
[36]	Matveyenko A V, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling[J]. Diabetes, 2012, 61(9):2269-79.
[37]	Ramakrishnan S K, Khuder S S, Al-Share Q Y, et al. PPARα (Peroxisome Proliferator-activated Receptor α) Activation Reduces Hepatic CEACAM1 Protein Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition[J]. The Journal of biological chemistry, 2016, 291(15):8121-9.
[38]	Najjar S M, Caprio S, Gastaldelli A. Insulin Clearance in Health and Disease[J]. Annual review of physiology, 2023, 85:363-81.
[39]	Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD-more than inflammation[J]. Nature reviews Endocrinology, 2022, 18(8):461- 72.
[40]	Ruck L, Wiegand S, Kühnen P. Relevance and consequence of chronic inflammation for obesity development[J]. Molecular and cellular pediatrics, 2023, 10(1):16.
[41]	Hayakawa F, Soga K, Fujino J, et al. Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium[J]. Biochemistry and biophysics reports, 2023, 36:101575.
[42]	Kakino S, Ohki T, Nakayama H, et al. Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model[J]. Hormone and metabolic research=Hormon- und Stoffwechselforschung=Hormones et metabolisme, 2018, 50(1):80-7.
[43]	Deangelis A M, Heinrich G, Dai T, et al. Carcinoembryonic antigen-related cell adhesion molecule 1:a link between insulin and lipid metabolism[J]. Diabetes, 2008, 57(9):2296-303.
[44]	Park S Y, Cho Y R, Kim H J, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1[J]. American journal of physiology Endocrinology and metabolism, 2006, 291(3):E517-24.
[45]	Al-Share Q Y, Deangelis A M, Lester S G, et al. Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance[J]. Diabetes, 2015, 64(8):2780-90.
[46]	Wang Z, Sun T, Yu J, et al. FGF21:A Sharp Weapon in the Process of Exercise to Improve NAFLD[J]. Frontiers in bioscience (Landmark edition), 2023, 28(12):351.
[47]	Bakker L E, Van Schinkel L D, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men[J]. Diabetes, 2014, 63(1):248-58.
[48]	Pezzino S, Sofia M, Mazzone C, et al. Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends[J]. Scientific reports, 2024, 14(1):799.
[49]	Park D J, Sung P S, Kim J H, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1[J]. Journal for immunotherapy of cancer, 2020, 8(1).
[50]	Khairnar V, Duhan V, Patil A M, et al. CEACAM1 promotes CD8(+) T cell responses and improves control of a chronic viral infection[J]. Nature communications, 2018, 9(1):2561.
[51]	Adams D H, Eksteen B. Aberrant homing of mucosal T cells and extraintestinal manifestations of inflammatory bowel disease[J]. Nature reviews Immunology, 2006, 6(3):244-51.
[52]	He R, Zhao S, Cui M, et al. Cutaneous manifestations of inflammatory bowel disease:basic characteristics, therapy, and potential pathophysiological associations[J]. Frontiers in immunology, 2023, 14:1234535.
[53]	Horst A K, Wegscheid C, Schaefers C, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice[J]. Hepatology (Baltimore, Md), 2018, 68(1):200-14.
[54]	Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease:Current Evidence and Perspectives[J]. Biomolecules, 2021, 12(1).
[55]	Chen L, Chen Z, Baker K, et al. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction[J]. Immunity, 2012, 37(5):930-46.
[56]	Gruzdev S K, Podoprigora I V, Gizinger O A. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD):mechanisms, bacteria, and novel therapeutic targets[J]. Archives of microbiology, 2024, 206(2):62.
[57]	Najjar S M, Perdomo G. Hepatic Insulin Clearance:Mechanism and Physiology[J]. Physiology (Bethesda, Md), 2019, 34(3):198-215.
[58]	Salehi M, Aulinger B, Prigeon R L, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes[J]. Diabetes, 2010, 59(6):1330-7.
[59]	Ghadieh H E, Muturi H T, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis[J]. Hepatology communications, 2018, 2(1):35-47.
[60]	Ghadieh H E, Muturi H T, Najjar S M. Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism[J]. Journal of diabetes and treatment, 2017, 2017(4).

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 24
HTML全文浏览量: 3
PDF下载量: 0
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

CEACAM1在代谢功能障碍相关脂肪性肝病中的作用

doi: 10.12290/xhyxzz.2024-0035

通讯作者:
郭庆红,E-mail:gqh@lzu.edu.cn

计量

The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease

计量

目录

留言板

CEACAM1在代谢功能障碍相关脂肪性肝病中的作用

doi: 10.12290/xhyxzz.2024-0035

通讯作者: 郭庆红,E-mail:gqh@lzu.edu.cn

计量

出版历程

The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease

计量

出版历程

目录

通讯作者:
郭庆红,E-mail:gqh@lzu.edu.cn